Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)The U.S. is expected to be the first region to start selling pneumonia drugs in pipeline and later on, penetration of pneumonia drugs would occur in Europe.
By: Koncept Analytics The U.S. is expected to be the first region to start selling pneumonia drugs in pipeline and later on, penetration of pneumonia drugs would occur in Europe. The U.S. and Europe have high prevalence of severe forms of multiple drug resistance (MDR) organism which would result into a high demand for pneumonia drugs in future. The global pneumonia market is expected to grow in future with growing ageing population, increasing pharmaceutical R&D spending, increasing healthcare expenditure, accelerating economic growth, growing children population and rise in multiple drug resistance (MDR) organisms. Key trends of this market include progressing drug under pipeline, innovation in treatment options and increased preference towards combination therapy. However, there are some factors which can hinder growth of the market including stringent regulations and entry of generic drugs. The report "Global Pneumonia Market: Industry Analysis & Outlook (2018-2025)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan Plc, The Medicines Company and Nabriva Therapeutics. List of Charts Classification of Pneumonia Global Lefamulin Drug Revenue Forecast (2019-2025) Global ASN100 Drug Revenue Forecast (2021-2025) The U.S. CAP Patient Population Forecast (2017-2022) The U.S. CAP Patient Population by Category (2017) The U.S. CAP Outpatient Population Forecast (2017-2022) The U.S. CAP Hospital Patient Population Forecast (2017-2022) The U.S. HAP/VAP Population Forecast (2022-2025) The U.S. Lefamulin Drug Revenue Forecast by Category (2019-2025) The U.S. Lefamulin Drug Revenue Forecast By Patient Type for CAP (2019-2025) The U.S. Lefamulin Drug Revenue Forecast for HAP/VAP (2022-2025) The U.S. ASN100 Drug Revenue Forecast for VAP (2021-2025) Europe CAP Patient Population Forecast (2017-2022) Europe CAP Patient Population by Category (2017) Europe CAP Hospital Patient Population Forecast (2017-2022) Europe CAP Outpatient Population Forecast (2017-2022) Europe VAP Patient Population Forecast (2021-2025) Europe Lefamulin Drug Revenue Forecast by Patient Type for CAP (2021-2025) Europe ASN100 Drug Revenue Forecast for VAP (2022-2025) Global Ageing Population (2012-2017) Global Pharmaceutical R&D Spending (2013-2017) Global Healthcare Expenditure (2012-2017) Global GDP Per Capita (2012-2017) Global Children Population (2012-2017) Global Pneumonia Market Key Players - Market Cap Comparison (2016) Nabriva Therapeutics Net Revenue and Net Income (Loss) (2013-2016) Nabriva Therapeutics Research and Development Expenditure (2014-2016) Merck & Co., Inc. Revenue Share by Segments (2016) Merck & Co., Inc. Net Revenue and Net Income (2012-2016) Merck & Co. Research and Development Expenditure (2014-2016) Allergan Plc Revenue Share by Segments (2016) Allergan Plc Net Revenue and Net Income (2012-2016) Allergan Plc Research and Development Expenditure (2014-2016) The Medicines Company Revenue Share by Products (2016) The Medicines Company Net Revenue and Net Income (Loss) (2012-2016) The Medicines Company Research and Development Expenditure (2014-2016) List of Tables Drugs under Development for Pneumonia (2017) Global Pneumonia Market Key Players - Revenue Comparison (2016) Allergan Plc Agreements (2016) For more Information: http://www.konceptanalytics.com/ Koncept Analytics Vikas Gupta (Business Development Manager) FFCS-36, Ansal Plaza Vaishali, Ghaziabad U.P - 201010 Tele: +91-120-4130959 Mobile: +91-9871694789 Mail ID – vikas@konceptanalytics.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|